2018
DOI: 10.1002/wps.20517
|View full text |Cite
|
Sign up to set email alerts
|

Increasing expectations and knowledge require a more subtle use of prophylactic antipsychotics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(7 citation statements)
references
References 9 publications
0
7
0
Order By: Relevance
“…Despite skepticism in the field (Catts & O'Toole, 2017; Correll, Rubio, & Kane, 2018; Goff et al, 2017; Leucht & Davis, 2017), a major factor, among multiple other possible factors, that may be contributing to the negative outcomes in patients experiencing long-term antipsychotic treatment is antipsychotic-induced dopamine super-sensitivity psychosis (aiDSP) (Chouinard et al, 2017; Fallon, Dursun, & Deakin, 2012; Murray & Di Forti, 2018; Nakata, Kanahara, & Iyo, 2017; Yin, Barr, Ramos-Miguel, & Procyshyn, 2017). The Chicago Follow-up Study was completed before clinical scales for assessing aiDSP had been fully developed (Demjaha, Murray, McGuire, Kapur, & Howes, 2012; Oda, Kanahara, & Iyo, 2015; Suzuki et al, 2015; Vita et al, 2019), and then used in large scale follow-up studies of continuous antipsychotic treatment showing that 30% of patients with schizophrenia and 70% of patients with treatment-resistant schizophrenia developed aiDSP (Chouinard & Chouinard, 2008; Takase et al, 2015).…”
Section: Discussionmentioning
confidence: 99%
“…Despite skepticism in the field (Catts & O'Toole, 2017; Correll, Rubio, & Kane, 2018; Goff et al, 2017; Leucht & Davis, 2017), a major factor, among multiple other possible factors, that may be contributing to the negative outcomes in patients experiencing long-term antipsychotic treatment is antipsychotic-induced dopamine super-sensitivity psychosis (aiDSP) (Chouinard et al, 2017; Fallon, Dursun, & Deakin, 2012; Murray & Di Forti, 2018; Nakata, Kanahara, & Iyo, 2017; Yin, Barr, Ramos-Miguel, & Procyshyn, 2017). The Chicago Follow-up Study was completed before clinical scales for assessing aiDSP had been fully developed (Demjaha, Murray, McGuire, Kapur, & Howes, 2012; Oda, Kanahara, & Iyo, 2015; Suzuki et al, 2015; Vita et al, 2019), and then used in large scale follow-up studies of continuous antipsychotic treatment showing that 30% of patients with schizophrenia and 70% of patients with treatment-resistant schizophrenia developed aiDSP (Chouinard & Chouinard, 2008; Takase et al, 2015).…”
Section: Discussionmentioning
confidence: 99%
“…However, they concluded that the evidence favored continuous antipsychotic use. In response to that study, several prominent researchers advised to “encourage a sense of curiosity about the possibility of dose reduction and discontinuation in appropriate patients ( Marder and Zito, 2018 ),” to have “guidelines to be developed on when and how slowly to reduce antipsychotics, and in whom it is appropriate to eventually stop them ( Murray and Di Forti, 2018 ),” and if guidelines are to be changed, “due to the subjectivity of psychiatric outcomes—there is room for interpretation, in the future the evidence will have to be presented such that patients can decide themselves” ( Leucht, 2018 ).…”
Section: Resultsmentioning
confidence: 99%
“…Echoing the advocacy of Marder and Zito: “We encourage a sense of curiosity about the possibility of dose reduction and discontinuation in appropriate patients.” [ 52 ], as well as the advocacy of Murray and Di Forti: “Guidelines need to be developed on when and how slowly to reduce antipsychotics, and in whom it is appropriate to eventually stop them.” [ 53 ], this report employs a visual presentation to recognize and define the patterns of dose-tapering trajectories along a zigzag path. The proposed naming provides a framework to depict individual patient’s course.…”
Section: Discussionmentioning
confidence: 99%